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PATIENTS AND METHODS

Patients
Fifty-two men and 48 women were studied. The men (mean age 56 years; range 18-72) were on average 2 years older than the women (range 14-87). Ninety-two of the patients were in the general surgical wards of Ninewells Hospital and the remainder in the wards of King's Cross Hospital for Infectious Diseases.
Trial Design
The trial was uncontrolled. Patients were admitted to it on the judgment of the clinician in charge. The clinician also decided the dose level to be given (500, 750 or 1000 mg, 8-hourly), the route (either i.v. or i.m.) and, after a minimum of 5 days, the length of tieatment. Patients were excluded from the trial if they had moderate or severe loss of renal or liver function; if they were known or thought to be hypersensitive to any of the cephalosporin antibiotics, or if they had suffered any severe hypersensitivity reaction to any of the penicillin antibiotics. The trial was approved by the local Ethical Committee. Its nature was explained to the patients and their agreement sought before treatment was begun. Assessment (1) Laboratory tests Before treatment and at the end of it, specimens were taken for measurement of hkmoglobin and total leucocyte count; serum bilirubin, serum alkaline phosphatase, aspartate transaminase y-glutamyltranspeptidase and serum creatinine; and for bacteriological examination. Where possible, sera were also taken on the first and fifth days of treatment, 45 min and 6 h after a dose of cefuroxime, for measurement of peak and trough serum levels. The cefuroxime content of these sera was assayed on 30 x 30 cm plates. Three aliquots of serum, diluted in phosphate-buffered saline (PBS) were placed at randon. as were standard solutions of cefuroxime in FJ IS. in wells cut in Oxoid DTS agar. To this was added sodium citrate to a final concentration of 3 g/l and Bacillus subtilis strain 1904E as test organism. The plates were incubated overnight at 37°C. Thereafter the concentration of cefuroxime in the test sera was calculated by regression line analysis from the observed zones of inhibition.
The minimal inhibitory concentration (MIC) of cefuroxime for strains isolated from the patients was measured by agar plate dilution using 9 cm diameter plates containing Oxoid DST agar incorporating concentrations of cefuroxime from 0.125-50 mg/I. For some strains, 5 % of saponin-lysed horse blood was added. The test strains were grown overnight in broth and applied with a multipoint inoculator delivering between 104 and 105 colony-forming units of each culture. Appropriate control strains of known sensitivity were included on each plate.
(2) Clinical assessment The patients were questioned about the duration and intensity of pain felt when cefuroxime was injected. Other subjective side effects were recorded when they were volunteered. The clinical response to treatment was recorded using a three-point scale on which (f) represented complete remission; (HI) improvement and (III) patients who were no better or worse.
RESULTS
Dose Levels and Duration ofTreatment
Seventy patients received 750 mg 8-hourly for an average of 7 days each (range 5-13 days). Twentyfive patients received 500 mg 8-hourly for an average of 6 days each (range 4-8 days) and 3 patients received 1000 mg 8-hourly for an average of 6 days each (range 4-7 days). Two patients were given 1000 mg 8-hourly for 2 and 3 days respectively, before each dose was reduced The findings for 8 patients have been omitted, 6 to whom cefuroxime was given prophylactically and 2 who (early in the trial and in error) were given other antibiotics at the same time. Seven patients had 2 infections and I had a triple infection. A total of 101 clinical episodes of illnesses were treated. In 89% there was clinical cure or improvement and in 11 % treatment with cefuroxime was apparently without effect. The poorest results were obtained in the small group of patients with soft tissue infections complicating severe peripheral vascular disease, 3 of whom eventually required amputation. Three patients died during the trial. Two were elderly men, one of whom developed a chest infection after partial cystectomy for carcinoma of the bladder and the second, with severe chronic obstructive airways disease, who developed acute respiratory infection and died after only 4 days of treatment. The third was a 50 year old man who developed a wound infection after a laparotomy at which was found widespread dissemination of a carcinoma of the small bowel. He died at the end of 13 days of treatment.
Serum levels ofCefuroxime
Cefuroxime was assayed in 67 samples of serum from 23 patients. Four trough samples and 5 peak samples from patients receiving 500 mg 8-hourly had mean values of 1.7 and 11.5 mg/ litre respectively. Twenty-eight trough samples and 30 peak samples from patients receiving 750 mg 8-hourly had mean values of 7 and 25.1 mg/l respectively. There was no significant difference, in individual patients, between the levels found in samples taken on the first and fifth days of treatment.
Bacteriological Results
The MICs of cefuroxime for 99 of the bacterial strains isolated from the patients are shown in Table 2 . Of the strains 78% were inhibited by 4 mg/l or less, i.e. less than the trough level found in patients receiving 750 mg 8-hourly, and 87% were inhibited by 20 mg/I or less i.e. less than the peak level found in patients on the same dose regimen.
Appropriate and assessable bacteriological specimens were obtained in 48 of the clinical episodes treated. In 30 of these cefuroxime treatment was followed by bacteriological cure i.e. eradication of a pathogen (Table 3 ). In 18, it was without effect, a pathogen of the same (Table 4 ). In general there was good agreement between the bacteriological result and the clinical outcome in individual patients (Tables 3 and 4) .
Bacteriological success or failure was not determined by the age or sex of the patients, by the MIC of the infecting organism, nor surprisingly, by the dose level or length of treatment. It was not possible to decide if individual serum levels were related to outcome except in 3 of the 4 patients with soft-tissue infections complicating severe peripheral vascular disease. Their mean trough and peak levels were 6 and 21.5 mg/I respectively. Their infections were caused by strains sensitive to 2 mg/l or less of cefuroxime and yet this group was least successful, clinically and bacteriologically.
There was no instance during treatment of selection of cefuroxime-resistant variants and one only instance of superinfection. That occurred in a 69 year old woman who developed a staphylococcal wound infection after resection of an aortic aneurysm. Wound swabs at the end of treatment yielded a heavy growth of Pseudomonas aruginosa but no Staphylococci. The wound healed without further antibiotic treatment.
Side EjJects
(1) Subjective When questioned, all but 5 of the patients found injections of cefuroxime slightly or moderately painful, but the pain seldom lasted longer than 2-3 min and was never severe enough to justify either stopping treatment or the addition of local anesthetic. Five patients each complained on I occasion of drowsiness after an injection and one other patient (also on 1 occasion) complained of undue stiffness at the injection site in the thigh.
(2) Objective In 26 patients, whose underlying disease did not offer an immediate explanation, the results of one or more tests of liver function became abnormal or increasingly abnormal during treatment with cefuroxime. In 16 patients the rise was limited to the results for one test, in 14 of them to the test for y-glutamyltranspeptidase. In 7 patients levels of this enzyme and of aspartate transaminase rose during treatment, while one patient had rising levels in 3 tests and 2 patients rising levels in all 4.
Conclusions
During this study, cefuroxime was effective in 89% of the clinically diagnosed infections for which it had been prescribed and, where assessment was possible, its clinical effectiveness was closely matched by bacteriological cure. It was least effective in patients with severe peripheral vascular disease in whom tissue perfusion and penetration of antibiotic to the seat of infection are likely to be unsatisfactory.
Cefuroxime was well accepted and tolerated. Although painful when injected, the pain was short-lived and never severe. Objective evidence of toxicity was limited to rises in serum transaminases during treatment in 26 patients whose underlying disease did not offer an immediate explanation for these changes. In most, the rise was limited to y-glutamyltranspeptidase levels. While many of the patients had undergone major surgical operations, were often seriously ill and were suffering from infections (each of which might explain the rise in serum transaminase levels) further studies are necessary before it can be concluded that cefuroxime is not hepatotoxic.
There was one clinically unimportant instance of superinfection during treatment, but cefuroxime resistant variants were not isolated.
In a recent study in hospital patients Norrby et al. (1977) found that trough serum levels of cefuroxime were higher and peak serum levels lower than the levels found by O'Callaghan et al. (1976) in healthy volunteers receiving the same dose. Similar differences were found in the present study. It is probable that hospital patients absorb and excrete cefuroxime more slowly (although without accumulating it) than do healthy individuals. If these differences can be substantiated they can be used to define either the frequency or size of dose of cefuroxime to be recommended for treatment, or the MIC, which in turn defines a clinically sensitive isolate during routine testing in the diagnostic laboratory.
